Codex DNA announced the release of full-length synthetic genomes for two emerging variants of the SARS-CoV-2 virus. The new genomes include the B.1.1.7 variant that initially emerged in the United Kingdom and the B.1351 variant that was first detected in South Africa, according to a news release.
Synthetic genomes enable researchers to perform discovery and development efforts of SARS-CoV-2 and to develop breakthrough therapies and diagnostics for this pandemic-causing virus. They can also reduce or eliminate the costs and complexity of highly regulated biosecurity facilities required for studying a dangerous pathogen.
Together with previously released genomes, Codex DNA markets 12 SARS-CoV-2 synthetic genomes. These new variant genomes are IVT-ready and can be activated easily using established in vitro methods for use in developing or testing monoclonal antibody therapies or vaccines against these variants. These genomes can also serve as diagnostic controls specific to the UK and South Africa variants.
